Article
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Nature - 4 May 2017
Huang Alexander C, Postow Michael A, Orlowski Robert J, Mick Rosemarie, Bengsch Bertram, Manne Sasikanth, Xu Wei, Harmon Shannon, Giles Josephine R, Wenz Brandon, Adamow Matthew, Kuk Deborah, Panageas Katherine S, Carrera Cristina, Wong Phillip, Quagliarello Felix, Wubbenhorst Bradley, D'Andrea Kurt, Pauken Kristen E, Herati Ramin S, Staupe Ryan P, Schenkel Jason M, McGettigan Suzanne, Kothari Shawn, George Sangeeth M, Vonderheide Robert H, Amaravadi Ravi K, Karakousis Giorgos C, Schuchter Lynn M, Xu Xiaowei, Nathanson Katherine L, Wolchok Jedd D, Gangadhar Tara C, Wherry E John
Abstract excerpt
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used as indicators of clinical response; however, blood-based profiling to understand the mechanisms of PD-1 blockade has not been widely explored. Here we use immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.